Scientific research should be rigorous and not error-prone, but it is always difficult to avoid individual phenomena. Last week, Nature Methods published a critical article on CRISPR technology, claiming that the gene editing tool CRISPR has caused "unexpected mutations" in the mouse genome. The publication of the article led to a sharp fall in the stocks of two genetic editing companies: Intellia Therapeutics and Editas Medicine. Recently, the two companies expressed strong dissatisfaction with the article and thought that their conclusions were completely wrong and should not even be announced. The CEO of Intellia called for the article to be retracted and removed from the scientific literature. He said: "This publication has received great attention from the media and the public, causing significant losses to us. Given the experimental design and discussion of the results of the article, I think the "Nature Method" magazine should withdraw it." A spokesperson for the publisher of Natural Methods said that they have received some feedback on the article, and they are seriously considering and discussing relevant issues with the author. The author of the article did not respond directly. The article "Unpredictable Gene Mutations Caused by the Editing of CRISPR-Cas9 in Vivo" claims that gene editing tools have caused widespread and unpredictable damage in the process of editing mouse genes, introducing hundreds of unexpected genetic mutations. Once the article was published, it became the headline news. The stock market of Editas Pharmaceuticals, Intellia Therapeutics and CRISPR Therapy Company totaled more than $1 billion, but they all fell sharply after the news came out. On social platforms such as Twitter, some scientists quickly pointed out some basic errors in the article, including erroneous gene recognition, a small number of animal experiments, and most seriously, the article regards the animal's normal genetic differences as CRISPR. The results of the editor. Editas Chief Technology Officer and 11 other scientists jointly wrote that the experimental data does not support its conclusions. These scientists also include professors from Harvard University. They think the article is "very likely" to be revoked because the article ignores many key issues. CRISPR technology is hailed as "a revolutionary approach to genetic engineering," but sometimes its role is exaggerated, including claims that the technology can cure all genetic diseases and solve the world's food shortages. In fact, CRISPR can indeed modify specific DNA sequences to correct or alter genes. Although powerful, if there are identical or similar DNA sequences elsewhere in the genome, it may result in more random changes in DNA. Many people have expressed concerns about the potential side effects of the technology, including even the inventors of the technology. It is very dangerous to use CRISPR for treatment at will. If a target gene fragment is also in an important gene, a wrong gene excision can be catastrophic, but many scientists believe that locating the gene fragment can eliminate most of the risk. The ease of use of CRISPR means that almost any laboratory has conditions. China has begun experimenting with humans, but this rushing research may increase the likelihood of errors. Therefore, Editas postponed research on the use of CRISPR for the treatment of ocular diseases. However, Intellia believes that the author of this article ignores many of the findings of CRISPR, which are neither experts in CRISPR nor genome-wide sequencing or genetic geneticists, so the conclusion of this “unexpected mutation†is not scientific. The publisher stated that it might consider retracting the draft. Peripherally Inserted Central Catheter picc catheter line,picc line,Peripherally Inserted Central Catheter,1.9 fr picc line catheter Anesthesia Medical Co., Ltd. , https://www.honestymed.com